24/7 Market News Snapshot 14 May, 2025 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp. (NASDAQ:KTTA) has garnered significant market interest recently, evident from its notable pre-market trading surge to $0.994, a 15.58% increase from the previous close of $0.860, with an impressive volume of 3.61 million shares exchanged. This rise indicates robust investor enthusiasm, potentially linked to the company’s recent advancements, particularly in its clinical research initiatives.

The company is set to launch a Phase 1/1b open-label clinical study for PAS-004, a next-generation macrocyclic MEK inhibitor aimed at treating symptomatic and inoperable plexiform neurofibromas in adults with neurofibromatosis type 1 (NF1). The anticipated dosing of the first patient is expected in the second quarter of 2025. This pivotal study marks an important step in Pasithea’s mission to deliver innovative therapies for challenging health conditions.

The clinical trial will rigorously evaluate PAS-004’s safety, tolerability, pharmacokinetics, and pharmacodynamics while examining preliminary efficacy outcomes. Patients will be administered a starting dose of a 4mg tablet once daily, contributing to the comprehensive understanding of this promising treatment. Initial patient enrollment will commence at the first active site, with plans to expand to additional clinical locations in the near future.

Dr. Rebecca Brown, a member of Pasithea’s Scientific Advisory Board, highlighted the study’s design, anticipating positive implications for patients with NF1-related plexiform neurofibromas. She pointed out that the once-daily dosing regimen of PAS-004 could enhance patient adherence to treatment.

Pasithea’s CEO, Dr. Tiago Reis Marques, underscored the significance of this clinical trial not only for the company but also for the NF1 patient community. He expressed commitment to advancing PAS-004, particularly given its promising safety profile observed in earlier studies, thus addressing the unmet medical needs prevalent in the NF1 treatment landscape.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.